| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11239-013-0967-Z |
| P698 | PubMed publication ID | 23860880 |
| P2093 | author name string | Richard C Becker | |
| Tracy A DeWald | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues | Q24633406 | ||
| Structure-based design of novel potent nonpeptide thrombin inhibitors | Q27638874 | ||
| Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement | Q28245267 | ||
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
| Dose adjustment in patients with liver disease | Q28253557 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| New oral anticoagulants in atrial fibrillation | Q28261825 | ||
| Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity | Q28278166 | ||
| Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database | Q28294927 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Membrane transporters in drug development | Q29616802 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Apixaban metabolism and pharmacokinetics after oral administration to humans | Q33373622 | ||
| Direct thrombin inhibitors. | Q33393692 | ||
| Effects of food on clinical pharmacokinetics | Q33747102 | ||
| Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure | Q33815078 | ||
| Apixaban or enoxaparin for thromboprophylaxis after knee replacement | Q34018819 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein | Q34235311 | ||
| The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation | Q34298925 | ||
| Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future | Q34310938 | ||
| Role of transport proteins in drug absorption, distribution and excretion | Q34378917 | ||
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor | Q34381344 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells | Q34532617 | ||
| Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes | Q34582733 | ||
| Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate | Q34590281 | ||
| Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor | Q34611004 | ||
| Impact of OATP transporters on pharmacokinetics | Q34612244 | ||
| Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers | Q34615829 | ||
| Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers | Q34620374 | ||
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 | ||
| Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction | Q34819051 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| Understanding and controlling hepatobiliary function | Q35021188 | ||
| Considerations in the design and development of transport inhibitors as adjuncts to drug therapy | Q35048758 | ||
| Thrombin formation | Q35217249 | ||
| Organic anion-transporting polypeptide (OATP) transporter family and drug disposition | Q35594553 | ||
| Clinical relevance of P-glycoprotein in drug therapy | Q35620664 | ||
| The complexities of hepatic drug transport: current knowledge and emerging concepts. | Q35793721 | ||
| Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract | Q35827133 | ||
| Flavonoids in food and their health benefits | Q36023128 | ||
| Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense | Q36104162 | ||
| Transporters and drug therapy: implications for drug disposition and disease | Q36253732 | ||
| Inhibition of Factor Xa : a potential target for the development of new anticoagulants | Q36255247 | ||
| Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants | Q36322051 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants | Q36525260 | ||
| Effects of drug transporters on volume of distribution | Q37214523 | ||
| P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans | Q37626608 | ||
| P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations | Q37811964 | ||
| Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor | Q37841256 | ||
| Drug and dietary interactions of warfarin and novel oral anticoagulants: an update | Q37848142 | ||
| Novel oral anticoagulants and their role in clinical practice | Q37961824 | ||
| Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. | Q37970175 | ||
| Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors | Q37999699 | ||
| Intestinal drug transporters: an overview | Q38049926 | ||
| Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment | Q38079779 | ||
| Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial | Q38490930 | ||
| Physiologic considerations in drug absorption from the gastrointestinal tract | Q39746131 | ||
| Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study | Q39862966 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery | Q40923441 | ||
| The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects | Q41121441 | ||
| Carrier-mediated intestinal transport of drugs | Q41140046 | ||
| Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier | Q41160310 | ||
| Regulation and function of the multidrug resistance genes in liver. | Q41532387 | ||
| The physiological function of drug-transporting P-glycoproteins | Q41688645 | ||
| Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study | Q43137255 | ||
| Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. | Q43579744 | ||
| Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens | Q44787212 | ||
| Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport | Q44854938 | ||
| Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study | Q46550059 | ||
| The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans | Q46897672 | ||
| Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir | Q48932058 | ||
| Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation | Q50501245 | ||
| Differential propensity for major hemorrhagic events in patients with different types of arterial disease. | Q51021319 | ||
| Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. | Q51499148 | ||
| The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. | Q53229008 | ||
| Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. | Q53526711 | ||
| Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule | Q54338292 | ||
| High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. | Q54762269 | ||
| Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Q56620375 | ||
| Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs | Q60975926 | ||
| Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine | Q73794585 | ||
| In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate | Q80541082 | ||
| Factor Xa and thrombin as targets for new oral anticoagulants | Q83067930 | ||
| Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents | Q83080617 | ||
| In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban | Q83942064 | ||
| Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers | Q84213242 | ||
| Edoxaban: a new oral direct factor xa inhibitor | Q84810467 | ||
| Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial | Q85044094 | ||
| P433 | issue | 2 | |
| P921 | main subject | pharmacology | Q128406 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 217-233 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | The pharmacology of novel oral anticoagulants | |
| P478 | volume | 37 |
| Q90286372 | A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting |
| Q39251865 | Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. |
| Q92802219 | Atrial Fibrillation in Older People: Concepts and Controversies |
| Q61799153 | Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature |
| Q58180540 | Development and Validation of RP-UPLC Method for the Determination of Process and Degradant Impurities Present in Dabigatran Etexilate Mesylate Capsules Using High Strength Silica-T3 Sorbent Column |
| Q30277086 | Direct Oral Anticoagulants in Cirrhosis. |
| Q64916576 | Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report. |
| Q49647319 | Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. |
| Q38767250 | Management Overview: Taking a Patient with Intracranial Hemorrhage Related to Direct Oral Anticoagulants to the Operating Room. |
| Q38335784 | Molecular recognition in chemical and biological systems |
| Q55442446 | Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. |
| Q38793747 | Novel anticoagulants - an update on the latest developments and management for clinicians treating patients on these drugs |
| Q38589533 | Novel anticoagulants: general overview and practical considerations for dental practitioners |
| Q34666804 | Novel oral anticoagulants in non-valvular atrial fibrillation |
| Q38980059 | Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance |
| Q57807139 | Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture |
| Q38970312 | Reversal agents of non-vitamin K dependent anticoagulants: a rapid review of the changing horizon |
| Q58567443 | Routine coagulation test abnormalities caused by rivaroxaban: A case report |
| Q38203175 | The newer direct oral anticoagulants: a practical guide. |
| Q51088831 | Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. |
| Q38655960 | Who, when, and how to reverse non-vitamin K oral anticoagulants |
Search more.